Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT)

Several brokerages have updated their recommendations and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) in the last few weeks:

• 9/17/2025 – Summit Therapeutics is now covered by analysts at Barclays PLC. They set an “underweight” rating and a $13.00 price target on the stock.
• 9/16/2025 – Summit Therapeutics was given a new $13.00 price target on by analysts at Summit Redstone.
• 9/16/2025 – Summit Therapeutics is now covered by analysts at Barclays PLC. They set an “underweight” rating and a $13.00 price target on the stock.
• 9/16/2025 – Summit Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 9/8/2025 – Summit Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 9/8/2025 – Summit Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 9/3/2025 – Summit Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $40.00 price target on the stock.
• 9/3/2025 – Summit Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.
• 9/3/2025 – Summit Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $40.00 price target on the stock.
• 9/2/2025 – Summit Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 8/27/2025 – Summit Therapeutics had its price target raised by analysts at HC Wainwright from $44.00 to $50.00. They now have a “buy” rating on the stock.
• 8/19/2025 – Summit Therapeutics was given a new $21.00 price target on by analysts at Summit Redstone.
• 8/19/2025 – Summit Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock.
• 8/18/2025 – Summit Therapeutics is now covered by analysts at Piper Sandler. They set a “neutral” rating and a $21.00 price target on the stock.
• 8/16/2025 – Summit Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 8/15/2025 – Summit Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
• 8/14/2025 – Summit Therapeutics was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 8/12/2025 – Summit Therapeutics had its price target raised by analysts at Evercore ISI from $30.00 to $34.00. They now have an “outperform” rating on the stock.

Insider Activity at Summit Therapeutics

In other news, CEO Mahkam Zanganeh purchased 5,000 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were acquired at an average price of $18.07 per share, with a total value of $90,350.00. Following the purchase, the chief executive officer directly owned 556,093,090 shares of the company’s stock, valued at $10,048,602,136.30. The trade was a 0.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert W. Duggan bought 5,000 shares of Summit Therapeutics stock in a transaction that occurred on Thursday, September 11th. The stock was bought at an average cost of $18.07 per share, for a total transaction of $90,350.00. Following the purchase, the chief executive officer owned 556,093,090 shares in the company, valued at $10,048,602,136.30. This represents a 0.00% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 676,788 shares of company stock worth $11,969,512 in the last three months. Corporate insiders own 84.90% of the company’s stock.

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.